Effects of early-life exposure to THIP on phenotype development in a mouse model of Rett syndrome by Weiwei Zhong et al.
RESEARCH Open Access
Effects of early-life exposure to THIP on
phenotype development in a mouse model
of Rett syndrome
Weiwei Zhong, Christopher Mychal Johnson, Yang Wu, Ningren Cui, Hao Xing, Shuang Zhang and Chun Jiang*
Abstract
Background: Rett syndrome (RTT) is a neurodevelopmental disorder caused mostly by disruptions in the MECP2
gene. MECP2-null mice show imbalances in neuronal excitability and synaptic communications. Several previous
studies indicate that augmenting synaptic GABA receptors (GABAARs) can alleviate RTT-like symptoms in mice. In
addition to the synaptic GABAARs, there is a group of GABAARs found outside the synaptic cleft with the capability
to produce sustained inhibition, which may be potential therapeutic targets for the control of neuronal excitability
in RTT.
Methods: Wild-type and MECP2-null mice were randomly divided into four groups, receiving the extrasynaptic
GABAAR agonist 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrochloride (THIP) and vehicle control, respectively.
Low-dose THIP was administered to neonatal mice through lactation. RTT-like symptoms including lifespan, breathing,
motor function, and social behaviors were studied when mice became mature. Changes in neuronal excitability and
norepinephrine biosynthesis enzyme expression were studied in electrophysiology and molecular biology.
Results: With no evident sedation and other adverse side effects, early-life exposure to THIP extended the lifespan,
alleviated breathing abnormalities, enhanced motor function, and improved social behaviors of MECP2-null mice. Such
beneficial effects were associated with stabilization of locus coeruleus neuronal excitability and improvement of
norepinephrine biosynthesis enzyme expression.
Conclusions: THIP treatment in early lives might be a therapeutic approach to RTT-like symptoms in MECP2-null
mice and perhaps in people with RTT as well.
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Background
Rett syndrome (RTT) caused mostly by disruptions in
the MECP2 gene is a neurodevelopmental disorder oc-
curring in 1/10,000 live female births [1]. One of the
major consequences of the MECP2 disruption is brain-
stem dysfunction. [2–5]. In MECP2-null mice, several
groups of brainstem neurons including those in the locus
coeruleus (LC) show increased membrane excitability.
As a result of the excessive neuronal excitability, the bal-
ance of excitation and inhibition in local neuronal net-
works is impaired, affecting normal brainstem functions
for breathing control, cardiovascular regulation,
gastrointestinal activity, arousal, and locomotion, consist-
ent with RTT manifestations in humans [3, 6].
The increased neuronal excitability in the brainstem
is attributable to abnormal intrinsic membrane proper-
ties and deficiency in GABAergic synaptic inhibitions
[7–11]. In MECP2-null mice, both GABAA and GABAB
synaptic currents are reduced in LC neurons [9]. In
contrast, our recent studies indicate that extrasynaptic
GABAA currents are well retained in LC neurons of
MECP2-null mice [12], which is encouraging as the
extrasynaptic GABA receptors (GABAARs) may provide
an alternative pharmaceutical target to relieve the ex-
cessive neuronal excitability and its associated RTT
symptoms. Indeed, we have found that the extrasy-
naptic GABAAR agonist 4,5,6,7-tetrahydroisoxazolo[5,4-c]
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pyridin-3-ol hydrochloride (THIP) is beneficial to RTT-like
symptom relief inMECP2−/Y mice.
THIP or gaboxadol is an investigational drug, origin-
ally developed for insomnia. Clinical trials suggest that
THIP (10 mg/day) has no significant effects on sleep
onset and total sleep time [13]. It does have effects on
these measures in a higher dose (15 mg) where the ef-
fects are inconsistent between genders, and side effects
emerge including sedation and disorientation [13, 14].
Therefore, Merck and Lundbeck canceled further de-
velopment of the drug. It is not unusual, however, that
a preclinical drug fails in one application but succeeds
in another. The low efficacy of THIP on insomnia indeed
may be beneficial for its applications to RTT, as the un-
necessary sedation can be avoided. We have found that
intraperitoneal injection of THIP alleviates the breathing
abnormalities and extends lifespans of MECP2-null mice
[12]. However, intraperitoneal injection may introduce
stress and subject the animals to infection. To overcome
this potential problem, oral administration was given to
mice in this study. Also, we chose to use a low and
non-sedative dose of THIP to avoid potential side ef-
fects. RTT symptoms start 6–18 months after birth,
causing a loss of certain acquired motor and language
skills in humans. To intervene in this early period of
development, we exposed neonatal mice to THIP 1 day
after birth before the RTT-like symptoms manifest them-
selves. Therefore, this study was conducted in a way that
was close to therapeutic condition and very much differ-
ent from our previous study [12].
Methods
Animals
All experimental procedures were conducted in accordance
with the National Institutes of Health (NIH) Guide for the
Care and Use of Laboratory Animals and were approved
by the Georgia State University Institutional Animal Care
and Use Committee. Female heterozygous mice (genotype:
MECP2−/+; strain name: B6.129P2(C)-MECP2tm1.1Bird/J;
stock number 003890) from Jackson Lab were crossbred
with male C57BL/6 mice (wild type (WT)) to produce the
MECP2-null mice with the genotype MECP2−/Y. The PCR
protocol from Jackson Lab was used to identify the geno-
type. All experiments were done in male mice because the
MECP2−/Y males offer a completely MECP2-null condi-
tion that is not always available in MECP2−/+ females
owing to uncontrolled X-chromosome inactivation.
THIP administration
THIP was given to the mother in her drinking water
(200 mg/L) and then passed to pups of WT and MECP2−/Y
male mice via lactation [15]. This will last till weaning
at P18. After that, THIP was given through the pup’s
drinking water (20 mg/L) for another 5 weeks.
Brain slice preparation
Experiments were performed as we described previously
[7]. In brief, mice were decapitated after deep anesthesia
with inhalation of saturated isoflurane. The brain stem
was obtained and immediately placed in ice-cold and
sucrose-rich artificial cerebrospinal fluid (aCSF) contain-
ing (in mM) 220 sucrose, 1.9 KCl, 0.5 CaCl2, 6 MgCl2,
33 NaHCO3, 1.2 NaH2PO4, and 10 D-glucose. The solu-
tion was bubbled with 95 % O2 balanced with 5 % CO2
(pH 7. 40). The transverse pontine sections (150–250 μm)
containing the LC area were obtained using a vibratome
sectioning system and then recovered at 33 °C for 60 min
in normal aCSF containing (in mM) 124 NaCl, 3 KCl,
2 CaCl2, 2 MgCl2, 26 NaHCO3, 1.3 NaH2PO4, and 10
D-glucose. The brain slices were kept at room temperature
before use. During recording, the slices were perfused with
oxygenated aCSF at a rate of 2 ml/min and maintained
at 34 °C in a recording chamber by a dual automatic
temperature control (Warner Instruments).
Electrophysiology
Whole-cell current clamp was performed on LC neurons
in brain slices. Patch pipettes with resistance as 3–5 MΩ
were pulled with a Sutter pipette puller (Model P-97,
Novato, CA). Only the neurons with membrane poten-
tial less than −40 mV (LC neurons) and action potential
larger than 65 mV were accepted for further experi-
ments. The pipette solution contained (in mM) 130 K
gluconate, 10 KCl, 10 HEPES, 2 Mg-ATP, 0.3 Na-GTP,
and 0.4 EGTA (pH 7. 3). The bath solution was normal
aCSF bubbled with 95 % O2 and 5 % CO2 (pH 7. 40).
Recorded signals were amplified with an Axopatch 200B
amplifier (Molecular Devices, Union City, CA), digi-
tized at 10 kHz, filtered at 2 kHz, and collected with
the Clampex 8.2 data acquisition software (Molecular
Devices). Paired experiments were done by three people
double-blindly.
Membrane potentials were measured without any current
injection. The input resistance was calculated as the slope
of the linear portion in the I-V curve in response to a series
of injected pulse hyperpolarized currents (typically from
0.15 to 0 nA). The action potential overshoot was measured
as the amplitude from 0 mV to the peak of more than 20
events. The threshold was determined at the initiation point
of at least 20 spontaneous action potentials.
Quantitative PCR
Mice 5–7 weeks old were used in the experiments. Tran-
scripts were obtained from the pontine slices containing
the LC. Using complementary DNAs (cDNAs) synthesized
with the high-capacity cDNA reverse transcription kit
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(Life Technologies, Grand Island, NY), quantitative PCR
(qPCR) was performed with Fast SYBR® Green Master
Mix (Applied Biosystems, Life Technologies, New York,
NY) in a fast real-time PCR system (Applied Biosystems
7500) for 40 cycles. GAPDH was used as the internal
control for the quantification of tyrosine hydroxylase
(TH) and dopamine β hydroxylase (DBH) expression.
The following are PCR primers for the experiments:
GAPDH (forward: CCAGCCTCGTCCCGTAGA; reverse:
TGCCGTGAGTGGAGTCATACTG), TH (forward: TGG
CTGACCGCACATTTG; reverse: CCTGCACCGTAAGC
CTTCA), DBH (forward: TACCACAACCCACGGAAG
ATA; reverse: CGGTCAACACAAAGGCAGTCT), δ sub-
unit (forward: GGCTTCTTGGGCTTTACC; reverse: CA
CCCCCACTGTTTTTCTC), α6 subunit (forward: GAC
TTTGCCCATCGTTCC; reverse: TGCAAAAGCTACTG
GAAGAG), β1 subunit (forward: TGGTTTTCGATCTT
GTGTGTCAG; reverse: AGCCACCTCTCTCTTTGTGT




Pontine tissues containing the LC were obtained from
5- to 7-week-old mice and processed in RIPA buffer
(Sigma-Aldrich, St. Louis, MO) with 1 % protease in-
hibitor. BCA protein assay reagent (Pierce, Rockford,
IL) was used to estimate the protein concentrations
using 30 μg proteins to detect TH and DBH signals in
10 % SDS-PAGE gels and electrophoretically trans-
ferred to nitrocellulose membranes. The membranes
were then blocked for 2 h in 5 % non-fat milk and incu-
bated overnight at 4 °C with rabbit GAPDH primary
antibodies (1:10,000, Sigma-Aldrich, St. Louis, MO),
rabbit TH (1:1000, Sigma-Aldrich, St. Louis, MO), and
DBH primary antibodies (1:1000, Sigma-Aldrich, St. Louis,
MO). After being washed in PBS twice, the membranes
were incubated by horseradish peroxidase (HRP) conjugate
goat anti-rabbit secondary antibodies (1:5000, Life Tech-
nologies, Frederick, MD) for 1 h in room temperature. The
chemiluminescent detection system (Pierce) was used to
expose the membrane to films (Hy Blot CL; Denville,
Metuchen, NJ), and the photographs were scanned. The
immunoblotting signals were quantified using the ImageJ
software (NIH). TH and DBH signals were normalized to
the internal GAPDH controls.
Plethysmograph recording
Breathing activity of conscious mice was recorded with
the plethysmograph system consisting of a ~40 ml test
chamber, a reference chamber, and a force-electricity
transducer. The individual animal was kept in the test
chamber flowed by air at a rate of 60 ml/min. The mouse
was allowed to adapt to the chamber for at least 20 min
followed by a 20-min recording. The breathing activity
was recorded continuously as the barometrical changes
between the test chamber and the reference chamber with
the force-electricity transducer. The signal was amplified
and then collected with a Pclamp 9 software. The animals
were monitored via a video camera to ensure the wake
status during tests. The data analysis was done double-
blindly to the treatment. Apnea was considered only if
the breathing cycle lasts twice longer than the previous
one. Breathing frequency variation was calculated as
the ratio of standard deviation (SD) over the arithmetic
mean of breathing frequency. The SD and arithmetic
mean were measured from 200~300 successive breath-
ing events, which were randomly sampled from three
or four stretches with at least 50 breaths in each.
Grip strength
When lifted by the tail, the forelimbs of a mouse (age
5–6 weeks) were allowed to grasp the sensor lever of a
force-electricity transducer. The mouse was then gently
pulled upward by the tail until it released the grip.
Forces were continuously recorded with the Clampex 9
software. The grip strength of each mouse was measured
as the maximum force before lever release, and averaged
from three consecutive trails.
Grid walking
A mouse (age 5–6 weeks) was placed on the metal rigid
floor of a trial box (32 cm × 20 cm× 20 cm). The box was
elevated by 50 cm with the floor made of 11 × 11 mm
metal mesh. Mouse walking on the metal mesh floor was
videotaped for 5 min. In the video record, the limb place-
ment error was counted. A footfault was counted only
when a limb missed the metal floor bar (0.5 mm in diam-
eter) completely and went through the grid opening. The
footfault ratio was calculated by the overall number of
footfaults divided by the total steps including both fore-
limbs and hindlimbs.
Open field test
The experiment was performed as we described previ-
ously [16]. Mice aged 5–6 weeks were tested in an open
field chamber made of white plexiglass boards (50 cm L ×
50 cm W× 30 cm H) with 10 cm × 10 cm square lines.
Test animals were kept in their home cages and habitu-
ated for 30 min in the test room before testing. When
tested, each animal was placed in the center square and
allowed to move freely in the chamber. Spontaneous
locomotion activity was monitored by a video camera
for 5 min. With the video record, square crosses (all four
paws cross) were measured in each mouse. To eliminate
potential residual odors and potential contaminants, 70 %
ethanol was used to clean the apparatus followed by dd
H2O rinse after each test.
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Social interaction
Mice, age 6–7 weeks, were tested in a box (60 cm L ×
30 cm W× 40 cm H), in which there were three chambers
(20 cm L × 30 cm W× 40 cm H) separated with transpar-
ent walls. A door was arranged diagonally in each wall
allowing the tested mouse to travel freely in the chambers.
Before test, mice were placed in the test room for 30 min
habituation. Then sequential tests were performed in each
mouse. Firstly, the tested mouse was placed in the center
chamber and allowed to move freely over all three cham-
bers for 10 min. Its chamber preference was analyzed by
the time spent in each chamber. Secondly, the social be-
havior test was performed by introducing a random litter-
mate in one of the side chambers for 10 min, while times
that the tested mice spent with the mice were measured.
The littermate was randomly assigned in either side of the
chamber to avoid the side bias. Lastly, social novelty test
was performed by introducing a new stranger mouse in
the chamber and switching the familiar littermate to the
other chamber. The time spent in both side the chambers
were analyzed subsequently [17].
Lifespan
MECP2−/Y mice used in the experiment were randomly
selected and divided into two groups. One group was
treated with THIP containing water and the other treated
with regular water as vehicle control. Their lifespan were
monitored under identical living conditions. Their daily
activity and general physical conditions, including feeding,
movement, body weight, and interaction with other mice,
were observed. Death date of each mouse was recorded
when it occurred naturally or reached the humane end
point that was determined by staff members in the animal
facility at Georgia State University without any consult-
ation with the investigators. One outlier, which was 1.5
interquartile range (IQR) above the third quantile and
below the first quantile, was removed from each group to
minimize data variations.
Randomization/double blind
The animals used in the study were randomly separated
into a vehicle group and THIP group. The patch experi-
ments were done double-blindly by two to three people
without information of mouse genotype and treatment.
All the data analysis of behavior experiments, including
breathing activity, motor function, and social behavior,
were done with no information of the genotype and
treatment.
Data analysis
The sample sizes in the experiments were examined with
G-Power Analysis to yield sufficient statistical power. Data
are presented as means ± SE or median ± IQR. Mantel-Cox
test was used in the lifespan experiment. Kruskal-Wallis
test, Pearson correlation, and Spearman’s correlation were
used in the breathing experiments. ANOVA and Tukey’s
post hoc were applied in the behavior tests and electro-
physiology experiments. Student’s t test was performed to
analyze the data in the molecular experiments. Difference
was considered significant when P < 0.05.
Results
THIP administration
Symptoms of RTT patients and mouse models start after
a period of postnatal development. In MECP2-null mice,
breathing disorders started at 2–3 weeks after birth, and
defects in motor and social behaviors begin at 4–6 weeks
[18, 19]. Early intervention to extrasynaptic GABAARs
may affect the development of the symptoms. Therefore,
we started the THIP treatment of MECP2-null mice
from the birth day and maintained the level till mice
were fully mature.
The following strategies were used to determine THIP
dosing. (a) Based on water consumptions in our studies,
the dose given to the mother was 61.0 ± 2.2 mg/kg/day.
Consistent with previous studies, the mother with this
dose did not show any evident sedation neither any behav-
ioral alterations [15]. The infants received maximally one
tenth of the dose to the mother via lactation [20–22],
i.e., ~6 mg/kg/day. After weaning, these mice received
6.3 ± 0.4 mg/kg/day THIP in their drinking water, which
were also calculated based on their daily water intake.
(b) According to a THIP patent report, the LD50 in
mice is 320 mg/kg orally, which is 2.2 times higher than
i.p. (LD50 145 mg/kg) [23]. The THIP dose used in mouse
models of Angelman syndrome and Fragile X syndrome is
2–3 mg/kg i.p. [24–26], equivalent to 5–7 mg/kg in oral
after multiplication by 2.2, which is approximately the
same as used in our studies. (c) THIP pharmacokinetics
has been well studied in humans and laboratory animals
[27–30]. According to the visual observation, THIP treat-
ment had no evident effects on feeding, movement, body
weight, and other general physical conditions in both WT
and MECP2-null mice.
Lifespan
The lifespan of the mice was studied with THIP or vehicle
treatment. In the vehicle group, about 50 % of the
MECP2-null animals died at P52 with only 1 out of 14
tested animals surviving beyond P80. In contrast, MECP2-
null mice with THIP treatment reached 50 % fatality
(LD50) on P82, and one third (5 out of 15) mice lived
beyond P90 (Fig. 1a, b). When comparing LD50, the
THIP administration extended the lifespan of MECP2-
null mice by over 50 %, which was statistically significant
as well (Fig. 1a; P = 0.004, Mantel-Cox test). The same
THIP and vehicle treatments did not cause any lethality in
WT mice.
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Breathing abnormalities
Like people with RTT, MECP2-null mice developed severe
breathing abnormalities showing significantly high apnea
rate and high breathing frequency variation [6, 31], which
may lead to the early death or unexpected sudden death
seen in RTT patients and the RTT mouse model. It is
possible that the extended lifespan in MECP2-null mice
is attributable to the alleviation of breathing abnormal-
ities through THIP treatment. Therefore, we studied
mouse breathing activity using plethysmography. Early-
life administration of THIP prevented the development
of breathing abnormalities in MECP2-null mice (Fig. 2B,
D). In age 6–8 weeks, both the apnea rate and breathing
frequency variation were significantly reduced in MECP2-
null mice treated with THIP (Fig. 2A1, A2, C, E).
Motor function
The grip strength and grid walking tests were performed
to evaluate muscle strength and motor coordination, re-
spectively. Our results showed that in 5- to 6-week-old
MECP2-null mice, THIP treatment improved the grip
strength from 58.5 ± 2.1 g to 74.0 ± 1.7 g (Fig. 3a) and the
footfault ratio from 4.3 ± 0.5 % to 2.7 ± 0.2 % (Fig. 3b).
Both were significantly different from those of the vehicle
controls. These results were unlikely to be due to the
sedative effects of THIP, as in the open field test THIP did
not affect the spontaneous locomotion of either WT or
MECP2-null mice (Fig. 3c). Therefore, chronic treatment
of THIP moderated certain motor defects in MECP2-null
mice, such as muscle strength and motor coordination.
Social behaviors
The three-chambered tests are used widely in the studies
of sociability and social novelty [17]. In our current study,
only the animals showing no preference to either side
chamber during the exploration period were used for fur-
ther testing (Fig. 4a). Both of the WT and MECP2-null
mice in the experiments showed similar time spending in
the side chambers, indicating that none of the animals
were in the sedative state. THIP treatment did not alter
the chamber transitions or the chamber preference either
(Fig. 4b).
In the sociability test, we found that WT mice tended to
spend significantly longer time in the chamber with an
animal than without (267.9 ± 16.7 s in the animal chamber
vs. 155.9 ± 14.6 s in the empty chamber), whereas
MECP2-null mice in the vehicle group did not show such
preference (252.7 ± 36.3 s in the animal chamber 1 vs.
240.0 ± 39.4 s in the empty). THIP administration improved
significantly the social interaction or sociability of the
MECP2-null mice (313.5 ± 43.1 s in the animal chamber 1
vs. 153.5 ± 35.9 s in the empty) (Fig. 4c).
In the social novelty preference test, WT mice spent
significantly more time in the chamber with novel animals
than the chamber with the familiar one (349.3 ± 32.1 s in
the animal 1 chamber vs. 138.4 ± 22.8 s in the animal 2
chamber), whereas the MECP2-null mice did not show
such a preference (321.7 ± 44.1 s in the animal 1 chamber
vs. 200.9 ± 50.9 s in the animal 2 chamber). THIP treat-
ment improved significantly the social novelty preference
of the MECP2-null mice (386.7 ± 29.1 s in the animal 1
chamber vs. 122.2 ± 22.6 s in the animal 2 chamber)
(Fig. 4d), suggesting that THIP treatment seems to allevi-
ate the defects of sociability and social novelty as well.
Neuronal hyperexcitability
One of the common features of RTT in humans and ani-
mal models is the defect in the NE system [19, 32, 33].
Previous studies have shown that excitability of LC neu-
rons increases in MECP2-null mice [4, 7]. The LC neu-
rons are the main source of NE in the CNS, and play an
important role in breathing regulation, locomotion,
arousal, emotion, and other behaviors [3, 6, 34]. Therefore,
we chose these neurons to find whether THIP treatment
may stabilize their excitability in MECP2-null mice.
Fig. 1 THIP administration extended the lifespan of MECP2-null mice. a Twenty-nine MECP2-null mice were used in the survival experiment and 14 of
them were delivered THIP orally (solid line) and 13 without THIP treatment (dashed line). (**P < 0.01; Mantel-Cox test). b Percentage of survival in the
tested mice. In the vehicle group, 50 % MECP2-null mice died within 52 days, while THIP treatment expanded the 50 % lifespan to 82 days
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In the brain slice preparation, whole-cell current clamp
was performed in LC neurons from mice with and without
THIP pretreatment. Of four groups of mice, only the LC
neurons from MECP2-null mice in vehicle control showed
an obvious increase in spontaneous firing activity (Fig. 5A1,
A2, B1, B2). Detailed analysis of the passive and active
membrane properties showed that the THIP pretreatment
did not significantly change membrane potential, input re-
sistance, action potential overshoot, and firing threshold
of either groups of neurons (Fig. 5C, D, E, F). In MECP2-
null neurons, the spontaneous firing rate was significantly
higher than that in WT. The THIP pretreatment, however,
abolished the difference (vehicle: 3.1 ± 0.3 Hz and 5.1 ±
0.3 Hz; THIP: 3.6 ± 0.2 Hz and 3.7 ± 0.3 Hz; WT and
MECP2-null, respectively; Fig. 5G). Thus, these results
suggest that the LC neuronal hyperexcitability in MECP2-
null mice is significantly reduced after THIP exposure.
Gene expressions
Previous studies have shown that the MECP2 disruption
leads to reductions in NE content in the CNS and expres-
sion levels of the rate-limiting enzymes TH and DBH for
NE biosynthesis [4, 19, 35, 36]. Persistent hyperexcitation
of LC neurons may interfere with the homeostatic state in
NE biosynthesis and release, leading to the reduced ex-
pression of TH and DBH in MECP2-null mice [12]. Thus,
moderation of LC neuronal hyperexcitability may improve
expression of TH and DBH in MECP2-null mice. To test
this possibility, we studied the TH and DBH at mRNA
and protein levels. The qPCR analysis showed that THIP
treatment significantly increased both TH and DBH tran-
script levels in the pontine extracts of MECP2-null mice
(Fig. 6a–c). Western blot analysis showed a ~2-fold in-
crease in TH protein level and a ~1.5-fold increase in
DBH protein level (Fig. 6d–f ).
Fig. 2 THIP administration alleviated the breathing abnormalities in MECP2-null mice. A1, A2 Typical records of breathing activity from both WT
and MECP2-null mice with and without THIP administration. B Distributions of apnea count in different aged MECP2-null mice with and without
THIP treatment. C In MECP2-null mice, THIP administration significantly reduced the apnea count at ages of 4–6 weeks (vehicle: n = 26, THIP: n = 8,
P = 0.002) and 6–8 weeks (vehicle: n = 19, THIP: n = 8, P = 0.021), although the significance was not found in 2–4 weeks (vehicle: n = 45, THIP: n = 7,
P = 0.081; ###P < 0.001 in Kruskal-Wallis test; *P < 0.05, **P < 0.01 in Mann-Whitney post hoc comparison). D, E Similar effects of THIP treatment
on breathing frequency variation was observed in these mice (2–4 weeks: P = 0.037; 4–6 weeks: P = 0.004; 6–8 weeks: P < 0.001; *P < 0.05, **P < 0.01,
***P < 0.001; one-way ANOVA and Tukey’s post hoc)
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Early-life exposure to THIP might also reshuffle the
GABA receptor subunits. Therefore, quantitative PCR
was performed to detect the mRNA levels of δ, α6, β1,
and β2 subunits, which were reported as significantly
changed in MECP2-null LC area. In comparison with
vehicle control, a significant reduction of α6 subunit
was detected in MECP2-null mice with THIP treat-
ment, while no significant changes in other subunit ex-
pression were found (Fig. 7).
Discussion
In these studies, we have shown that early-life exposure
of the MECP2-null mice to a non-sedative dose of the
extrasynaptic GABAARs agonist THIP has several benefi-
cial effects on lifespan, breathing activity, motor function,
and social behaviors. Such alleviation of RTT-like symp-
toms by THIP treatment is associated with the stabilization
of neuronal excitability and enhancement of NE biosyn-
thetic enzymes in LC neurons.
The extrasynaptic GABAARs have several properties
different from the synaptic GABAARs, which may be
unique in interventions to neuronal excitability. They are
located outside the synaptic area, produce tonic or long-
lasting Cl− currents, show very little desensitization upon
activation, and are sensitive to some synaptic GABAAR
agonists and extrasynaptic GABAAR-specific agonists
[37–39]. They have the capability to change dynamically
their expression levels under different physiological and
pathophysiological conditions [12, 40, 41]. Manipulations
of these receptors with selective agents do not interrupt
GABAergic synaptic transmission mediated by the synap-
tic GABAARs. Thus, therapeutic activation of these extra-
synaptic GABAARs may avoid several side effects of the
synaptic GABAAR activators including sedation, tolerance,
and addiction.
People with RTT and the mouse models show the
delayed onset and progressive symptoms. Although the
mechanism for the delayed symptom onset remains
unclear, some factors may contribute to it, such as dy-
namic spatiotemporal relationship between MECP2 and
methylated DNA [42] and the altered allopregananal-
lone modulation of the GABA system during perinatal
period [8]. Thus, intervention to neuronal hyperexcit-
ability before the symptom onset may be a potential
way to prevent or delay the development of the disease.
The δ subunit containing extrasynaptic GABAARs are
expressed dynamically with growth [41]. Since severe
defects in the synaptic GABAAR system have been
demonstrated in mature MECP2-null mice, treatment
with THIP in early lives may be beneficial with respect
to enforcement of the inhibitory system in the neurode-
velopment of MECP2-null mice.
The reduced expression of α6 subunits suggests that
early treatment of THIP may lower the GABAR expression
Fig. 3 THIP administration improved motor function of MECP2-null
mice. a Significant main effects of THIP treatment (F = 23.74, df = 1,
P< 0.001) and genotype (F= 147.85, df= 1, P< 0.001) were observed, as
well as a significant interaction (F= 12.04, df= 1, P< 0.001). (###P< 0.001,
two-way ANOVA). The grip strength of MECP2-null mice was significantly
increased with THIP treatment (WT: n= 18 and n= 18 mice; MECP2-null:
n= 23 and n= 22; vehicle and THIP, respectively; ***P< 0.001, Tukey’s
post hoc). b Significant main effects of THIP treatment (F= 5.26, df= 1,
P< 0.05) and genotype (F= 30.4, df= 1, P< 0.001) were observed, as well
as a significant interaction (F= 13.25, df= 1, P< 0.001) (#P< 0.05, two-way
ANOVA). THIP administration significantly reduced the footfault ratio
(including both hindlimb and forelimb) of MECP2-null mice (WT: n = 22
and n = 23 mice; MECP2-null: n = 20 and n = 25; vehicle and THIP,
respectively; ***P < 0.001, Tukey’s post hoc). c The spontaneous
locomotion of WT and MECP2-null mice was not significantly affected
by THIP treatment. The main effect of THIP treatment was not significant
(F = 0.26, df = 1, P = 0.614), as the main effect of genotype (F = 3.00,
df = 1, P = 0.095). The interaction of these two factors was not
significant (F = 0.99, df = 1, P = 0.329) (WT: n = 8 and n = 7 mice;
MECP2-null: n = 9 and n = 6; vehicle and THIP, respectively;
two-way ANOVA)
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and the consequent GABAergic inhibition. The α6 sub-
unit is known to contribute to both the extrasynaptic
receptors together with the δ subunit and the synaptic
GABAARs with β and γ subunits [43, 44]. The reduc-
tion in these GABAARs might possibly lead to rebound
excitation after THIP withdrawal. The stabilization of
neuronal excitability, however, might affect cellular mech-
anisms reducing abnormalities, which could result in a
long-term reduction in neuronal hyperexcitabiltiy after
THIP withdrawal, contributing to the outcome of THIP in
breathing, motor function, social behaviors, and lifespan.
To minimize potential side effects of THIP, we chose
to use THIP chronically in low dosage. Although phar-
macokinetic studies were not performed in this report,
such information has been collected in previous studies
on mice, rats, dogs, and humans [27–30]. With a daily
dose of 10 mg in humans, THIP reaches the maximum
plasma concentration ~140 ng/ml in 2.0 h, and the
terminal plasma half-life time is 1.7 h [27]. Another pre-
clinical study in humans, rats, and mice shows a rapid
and complete absorption of THIP with the peak concen-
tration reached within 0.5 h in several organs include
the brain [29]. A clinical report indicates that therapeutic
dosages of THIP by long-term oral administration range
from 20 to 120 mg daily in human patients [45]. Higher
doses of THIP may cause adverse side effects, including
sedation, confusion, and dizziness [14]. In our present
study, the oral dose of THIP was calculated to be ~6 mg,
which appears effective for alleviating multiple RTT-like
symptoms in MECP2-null mice. Our test of spontaneous
locomotion supports the non-sedative effects of the dos-
age. The dosage given to the mother during lactation was
61.0 ± 2.2 mg/kg/day, which was also reported to have no
sedative effects neither behavioral alterations [15].
Similar to the dosages that we used in the study, several
previous studies have reported to use THIP for treatment
of mouse models of Fragile X syndrome and Angelman
syndrome. Since these diseases share multiple similarities
to RTT, such as impaired GABA system, neuronal hyper-
excitability, and autism-like symptoms [24, 26, 46], the
Fig. 4 THIP administration alleviated the defects of social behaviors in MECP2-null mice. During the habituation period in the three chamber test,
both WT and null mice took similar amount of times (a) and transitions (b) in either side of the chambers indicating no preference. The main
effect preference was not significant. (a F = 1.72, df = 1, P = 0.195; b F = 0.20, df = 1, P = 0.656; three-way ANOVA). The transitions between the
chambers also suggested that the tested animals are not in a sedative state. c In the sociability test, a significant difference was detected within
the main factor of preference (F = 23.31, df = 1, ###P < 0.001, three-way ANOVA). WT mice spent significantly more time in the chamber containing
an animal than the empty one, whereas the MECP2-null mice lost such a preference. THIP administration increased the time expenditure of
MECP2-null mice in interacting with another mouse (*P < 0.05; Tukey’s post hoc). No significant differences were found in the main factor of
genotype (F = 1.20, df= 1, P = 0.278) or THIP treatment (F = 0.03, df= 1, P = 0.863). The interactions of genotype × treatment (F = 0.46, df= 1, P = 0.500),
genotype × preference (F = 1.41, df = 1, P = 0.239), treatment × preference (F = 3.31, df = 1, P = 0.074), or genotype × THIP treatment × preference
(F = 2.08, df = 1, P = 0.155) were not significant as well (three-way ANOVA). d In the social novelty test, the main factor of preference showed
a significant difference (F = 54.48, df = 1, ###P < 0.001, three-way ANOVA). WT mice spent significantly more time in the chamber with a novel
animal than the chamber with a familiar one, whereas the MECP2-null mice did not show the preference to either chamber. With THIP treat-
ment the novelty preference was improved in the MECP2-null mice (**P < 0.01, ***P < 0.001; Tukey’s post hoc). No significant differences were
found in the main factor of genotype (F = 0.57, df = 1, P = 0.453) or THIP treatment (F = 0.17, df = 1, P = 0.681). The interactions of genotype ×
treatment (F = 0.02, df = 1, P = 0.888), genotype × preference (F = 0.49, df = 1, P = 0.487), treatment × preference (F = 1.58, df = 1, P = 0.213), or
genotype × THIP treatment × preference (F = 1.35, df = 1, P = 0.250) were not significant as well (vehicle: n = 12 and n = 9; THIP: n = 8 and n = 6;
WT and MECP2-null, respectively; three-way ANOVA)
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Fig. 5 (See legend on next page.)
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information shown in the present study is likely to benefit
to moving the drug for further clinical trials in all these
diseases.
LC neurons, the major NE source in the CNS, project
broadly to the other brain regions, including the medulla
where the respiratory center is located and the prefrontal
cortex where the NE system affects cognitive functions,
seizure, and social behaviors [47, 48]. In MECP2-null
mice with THIP treatment, the target regions of LC-NE
projection may benefit from the enhanced NE synthe-
sis, leading to the alleviation of the associated abnormal
behaviors. On the other hand, impaired neuron networks
were widely seen in MECP2-null mice [40, 49]. The social
defects of autism spectrum disorders were believed to be
correlated to the weak connections in the default net-
works including the medial prefrontal cortex and posterior
cingulate cortex [50]. With the beneficial effects found in
this study, we speculate that THIP might contribute to
reinforcement of these connections as well as amelioration
of the phenotypes.
In comparison to theMECP2-null mice, the most widely
used RTT mouse model, the MECP2−/+ mice tend to dis-
play large variations in RTT-like symptoms due to the
random X-chromosome inactivation. According to our
previous study, only 15–20 % MECP2−/+ mice in age 1-6
months showed the RTT-like symptom of breathing ab-
normalities, suggesting that the wild-type allele is not
randomly inactivated [2]. Generally, ~50 % the neurons in
the CNS of MECP2−/+ mice retained MECP2 expression
[51, 52], which may allow the MECP2−/+ mice to recapitu-
late the normal behaviors to some degree, compared to
the MECP2-null mice. However, the MECP2 mosaic ex-
pression pattern is not uniform in the CNS and it varies
between individuals, ages, and brain regions [51, 52]. Re-
gional expression levels of MECP2 was reported be cor-
related to the specific symptoms in the MECP2−/+
mice. Hippocampus MECP2 expression is related to the
exploratory activity behaviors and anxiety-like behav-
iors. Cortical MECP2 expression affects the general
symptomatic severity [53]. The age-dependent mosaic
(See figure on previous page.)
Fig. 5 THIP administration suppressed the hyperexcitability of LC neurons in MECP2-null mice. A1, A2 Typical recordings of spontaneous firing of LC
neurons in WT and MECP2-null mice at 1 month of age without THIP treatment. B1, B2 Spontaneous firing of LC neurons in WT and MECP2-null mice
of the same age with THIP pretreatment. C–F THIP administration did not significantly change membrane potentials, input resistance, action potential
overshoot, and action potential threshold in both WT and MECP2-null mice. No significant main effect of THIP treatment (F = 0.09, df = 1, P = 0.765;
F = 1.15, df= 1, P = 0.289; F = 0.27, df= 1, P = 0.606; F = 0.76, df= 1, P = 0.387; C, D, E, F, respectively) and genotype (F = 1.45, df = 1, P = 0.234; F = 0.09,
df= 1, P = 0.765; F = 0.01, df= 1, P = 0.921; F = 0.99, df= 1, P = 0.324; C, D, E, F, respectively) were observed, either the interaction (F = 0, df = 1, P = 1.000;
F = 1.46, df= 1, P = 0.232; F = 0.03, df= 1, P = 0.863; F = 3.58, df= 1, P = 0.064; C, D, E, F, respectively). G The main effect of genotype was significant
(F = 10.06, df= 1, P < 0.01), whereas the main effect of THIP treatment was not (F = 1.72, df= 1, P = 0.196). The interaction of these two factors was
significant (F = 8.6, df = 1, P < 0.01) as well (##P < 0.01; two-way ANOVA). The firing activity of LC neurons in MECP2-null mice is significantly increased
compared to the WT and chronic treatment with THIP abolished the hyperexcitability (vehicle: n = 14 and n = 13; THIP: n = 13 and n = 16; in WT and
MECP2-null, respectively; ***P < 0.001; Tukey’s post hoc)
Fig. 6 Improvement of TH and DBH expressions with THIP administration in MECP2-null mice. a-c, qPCR analysis showed that during THIP treatment
(P37), both TH and DBH transcript levels were significantly increased (vehicle: n = 4 and n = 4 animals; THIP: n = 5 and n = 5 animals; WT and
MECP2-null, respectively). d-f, The Western analysis also indicated that THIP treatment significantly increased the protein expressions of both
TH and DBH (vehicle: n = 4 and n = 4 animals; THIP: n = 4 and n = 4 animals; WT and MECP2-null, respectively; *P < 0.05, **P < 0.01, ***P < 0.001;
one-tailed Student’s t test)
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pattern suggests that even the X-chromosome inactiva-
tion ratio may also be affected by MECP2 deficiency in
the RTT mice brain and the consequent variation of
postnatal brain functions in RTT [51]. Thus, the age-
dependent and region-specific expression pattern of
MECP2 in the CNS contributes to the large variation of
the phenotypic outcome in MECP2−/+ mice, which all
need to be considered in studies of female RTT models.
Furthermore, MECP2−/+ mice usually develop the diag-
nostic symptoms when they become sexually mature. The
periodical hormone alternations in MECP2−/+ mice may
affect mouse performance in the behavioral tests compli-
cating the interpretation of the THIP effects. A previous
study reports significant variations in the open field, tail
flick, and suspension tests in female mice during their es-
trous cycle [54]. With all these complications in the fe-
male models, therefore, studies under MECP2-null
condition in the male model seems beneficial as the first
step of investigation before sophisticated preclinical trials
are conducted, which can be based on MECP2−/+ female
mice and may benefit from the experimental evidence ob-
tained from the male RTT models.
Selective restoration of MECP2 in GABAergic neurons
rescues multiple phenotypes in both MECP2−/Y and
MECP2−/+ mice [55], which suggests that the GABA system
is a feasible target to manipulate in RTT female mouse
model and RTT patients. Although the sexual difference of
LC neurons might be a concern of the potential effects of
THIP, a morphological study suggested female LC neurons
showed a higher frequency of communication with peri-LC
neurons in comparison to the male [56, 57], indicating that
THIP may have a greater effect in female RTT mouse
model or patients. A previous study reports that for some
unknown reasons, THIP tends to have a greater efficacy in
women than in men [13], further suggesting the potential
beneficial effects of THIP in RTT female mouse model
and patients. Nevertheless, further studies on MECP2−/+
mice are needed, which may be conducted as deliberate,
thorough, and systematic investigations that might
benefit from our findings in the male model.
Conclusions
Consistent with our previous study showing that the daily
injection of THIP in a high dose alleviates breathing ab-
normalities by stabilizing the neuronal activity [12], our
current study shows that early-life exposure to a low dose
of THIP affects multiple RTT-like symptoms. The early-
life exposure to THIP extends the lifespan of MECP2-null
mice, reduces breathing disorders and motor dysfunction,
and improves social behaviors. These beneficial effects are
associated with suppression of hyperexcitability and im-
provement of biosynthesis enzyme expression in MECP2-
null LC neurons. These results suggest that THIP has
beneficial effects on RTT-like symptoms in the mouse
model with complete knockout of the MECP2 gene.
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